Clinical trials: Genetic Testing
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Heart Disease, Susceptibility to, 5, Prediabetic State
Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
The purpose of this study is to examine whether the use of genetic test information and/or health coaching in patient risk counseling for heart disease and diabetes affect health behaviors and health outcomes in active-duty Air…
- Trial name
- NCT01884545
- Testing
- Health coaching, Genetic risk counseling, Standard risk assessment
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Duke University
Nevi
Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
This project is a multicenter study in which we will investigate a dual concept of nevogenesis. Study location is the Department of Dermatology at the Medical University of Graz in collaboration with centers in Austria (Vienna)…
- Trial name
- NCT00422448
- Testing
- To test the frequency of BRAF and NRAS mutations among nevi
- Where
- Austria
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Cystic Fibrosis
Blood Flow and Vascular Function in Cystic Fibrosis
Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections.
- Trial name
- CF-FLOW (NCT02057458)
- Testing
- Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Augusta University
Congenital Sucrase-isomaltase Deficiency (CSID)
Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Congenital sucrose-isomaltase deficiency (CSID) is a rare, genetic disease in which mutations in the sucrose-isomaltase (SI) gene cause digestion problems of sucrose resulting in diarrhea and abdominal pain.
- Trial name
- CSID GPS (NCT01914003)
- Where
- 19 sites in United States
- Volunteers
- 53 people
- Sponsor
- QOL Medical, LLC
Chronic Kidney Disease, Hypertension
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States
GUARDD-US is a prospective, multicenter, unblinded, two arm randomized pragmatic clinical trial. Participants will be randomized in a 1:1 ratio to immediate APOL1 gene testing and return of results (ROR) to participant and…
- Trial name
- GUARDD-US (NCT04191824)
- Testing
- Timing of return of results
- Where
- 14 sites in United States
- Volunteers
- 6,789 people
- Sponsor
- Duke University
G6PD Deficiency
Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood
The primary objective of the study is to assess the accuracy of the SD Biosensor STANDARD™ point-of-care (POC) G6PD test in measuring G6PD activity and classifying results compared to a reference assay and across repeated…
- Trial name
- NCT04054661
- Testing
- SD Biosensor STANDARD G6PD Test, Pointe Scientific Test Kit, HemoCue System
- Where
- United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- PATH
Blood Coagulation Disorders
Clinical and Economic Implications of Genetic Testing for Warfarin Management
The purpose of this study is to explore how knowing genes that individuals inherit from their parents can make warfarin dosing more safe and effective.
- Trial name
- NCT00964353
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- University of Chicago
Phenylketonuria
Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period
The primary objective of the study is to evaluate the proportion of responders (that is, greater than or equal to [>=] 30 percent reduction from Baseline in blood phenylalanine [Phe] level) to treatment with Kuvan® (sapropterin…
- Trial name
- ENDURE (NCT01082328)
- Testing
- Kuvan®
- Where
- Norway
- Volunteers
- 59 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390826
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Cystic Fibrosis
Effects of Sildenafil on CFTR-dependent Ion Transport Activity
Dehydrated airway surfaces resulting from sodium hyperabsorption and lack of chloride secretion are critical to the pathology that leads to the morbidity and mortality from Cystic Fibrosis (CF) lung disease.
- Trial name
- NCT01132482
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Jewish Health
Diabetes Mellitus
Genetic Testing for Type 2 Diabetes
In this 6-month randomized, controlled trial, we examined whether providing participants with genetic test results and counseling regarding their risk for type 2 diabetes would motivate them to improve their health behaviors and…
- Trial name
- NCT01060540
- Testing
- genetic testing for type 2 diabetes, Conventional risk counseling, eye disease counseling
- Where
- United States
- Volunteers
- 601 people
- Sponsor
- US Department of Veterans Affairs
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439123
- Testing
- Capivasertib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Pregnancy
PGT-A Versus Blastocyst Morphology Selection
Introduction Embryo aneuploidy is likely the leading cause of implantation failure in IVF cycles. Since the inception of IVF, non-invasive morphology based scoring has been the most widely used embryo selection method, resulting…
- Trial name
- NCT03095053
- Testing
- comprehensive chromosome screening
- Where
- Turkey (Türkiye)
- Volunteers
- 302 people
- Sponsor
- Antalya IVF
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06360575
- Testing
- Biopsy Procedure, Biospecimen Collection, Crizotinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Dermatitis, Atopic
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
- Trial name
- NCT03822832
- Testing
- BI 655130
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 51 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Colorectal Cancer
Michigan Genetic Hereditary Testing (MiGHT)
The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining…
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- MiGHT (NCT05162846)
- Testing
- Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
- Where
- United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma
- Trial name
- NCT03155620
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 172 sites in United States, Australia and 2 more
- Volunteers
- 1,377 people
- Sponsor
- National Cancer Institute (NCI)
Genetic Predisposition
Care Plans for Cancer Predisposition
Develop and evaluate acceptability, feasibility, and preliminary efficacy of digital care plan and accompanying text message reminders for children and adolescents with a known Cancer Predisposition Syndromes (CPS).
- Trial name
- NCT05736497
- Testing
- Digital Care Plans
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Children's Hospital of Philadelphia
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has a has a genetic change called NF1 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439318
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)